Human Investing LLC Has $553,000 Stock Holdings in Abbott Laboratories (NYSE:ABT)

Human Investing LLC decreased its stake in shares of Abbott Laboratories (NYSE:ABT) by 13.7% during the 4th quarter, Holdings Channel reports. The firm owned 5,020 shares of the healthcare product maker’s stock after selling 795 shares during the period. Human Investing LLC’s holdings in Abbott Laboratories were worth $553,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ABT. Signature Resources Capital Management LLC bought a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $29,000. Stuart Chaussee & Associates Inc. lifted its position in shares of Abbott Laboratories by 236.0% during the 4th quarter. Stuart Chaussee & Associates Inc. now owns 336 shares of the healthcare product maker’s stock valued at $37,000 after acquiring an additional 236 shares during the period. Rise Advisors LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at $37,000. Private Wealth Management Group LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at $44,000. Finally, Cornerstone Planning Group LLC lifted its position in shares of Abbott Laboratories by 79.4% during the 3rd quarter. Cornerstone Planning Group LLC now owns 454 shares of the healthcare product maker’s stock valued at $44,000 after acquiring an additional 201 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In other news, VP John A. Jr. Mccoy sold 472 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the completion of the sale, the vice president now directly owns 18,760 shares of the company’s stock, valued at $2,223,060. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, VP John A. Jr. Mccoy sold 472 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $118.50, for a total transaction of $55,932.00. Following the completion of the sale, the vice president now directly owns 18,760 shares of the company’s stock, valued at $2,223,060. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 963 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $114,115.50. Following the completion of the sale, the executive vice president now directly owns 125,697 shares of the company’s stock, valued at $14,895,094.50. The disclosure for this sale can be found here. Insiders sold a total of 34,384 shares of company stock valued at $3,653,916 over the last ninety days. 0.47% of the stock is currently owned by insiders.

Abbott Laboratories Trading Down 0.3 %

Shares of ABT stock traded down $0.28 on Monday, hitting $103.95. The company had a trading volume of 4,455,800 shares, compared to its average volume of 5,639,877. The firm has a market cap of $180.83 billion, a P/E ratio of 32.38, a P/E/G ratio of 2.50 and a beta of 0.76. The stock’s 50-day moving average is $108.08 and its two-hundred day moving average is $109.74. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.11 and a current ratio of 1.60. Abbott Laboratories has a twelve month low of $89.67 and a twelve month high of $121.64.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 EPS for the quarter, beating the consensus estimate of $0.96 by $0.02. The company had revenue of $9.96 billion for the quarter, compared to analyst estimates of $9.88 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.96%. The firm’s revenue for the quarter was up 2.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.03 EPS. On average, equities research analysts anticipate that Abbott Laboratories will post 4.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Barclays lowered their price target on Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating for the company in a report on Monday, April 22nd. Evercore ISI boosted their price target on Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Citigroup lowered their price target on Abbott Laboratories from $128.00 to $119.00 and set a “buy” rating for the company in a report on Wednesday, May 22nd. Raymond James reissued a “buy” rating and set a $124.00 price target on shares of Abbott Laboratories in a report on Wednesday, April 24th. Finally, Royal Bank of Canada lowered their price target on Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating for the company in a report on Thursday, April 18th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $120.60.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.